Baseline Assessment

2001 ◽  
Vol 8 (2) ◽  
pp. 273-274
Keyword(s):  
2017 ◽  
Vol 6 (3) ◽  
pp. 243-251 ◽  
Author(s):  
Philip Schatz ◽  
R. J. Elbin ◽  
Melissa N. Anderson ◽  
Jennifer Savage ◽  
Tracey Covassin

2021 ◽  
Author(s):  
Landon B. Lempke ◽  
Robert C. Lynall ◽  
Melissa N. Anderson ◽  
Michael A. McCrea ◽  
Thomas W. McAllister ◽  
...  

Author(s):  
Eduardo Romano ◽  
Mariana Sanchez ◽  
Eileen P. Taylor ◽  
Rosa Babino

The overarching aim of this study is to assess driving while impaired by alcohol (DWI) and riding with an impaired driver (RWID) rates among young adult Latinx immigrants to Miami-Dade County, Florida, within a year of arrival in the U.S.A. More specifically, this study aims to: (i) describe the demographic and socioeconomic characteristics of Latinx immigrants to Miami-Dade County within a year of arrival; (ii) examine their alcohol use, DWI, and RWID; and (iii) identify factors influencing these behaviors. This study uses baseline data from an ongoing National Institutes of Health-funded longitudinal study examining drinking and driving trajectories among young adult recent Latinx immigrants to Miami-Dade County. During the baseline assessment, retrospective pre-immigration data and post-immigration data were obtained via personal interviews. Inclusion criteria included being a Latinx immigrant, 18–34 years old, who recently immigrated (within one year before baseline assessment) to the U.S.A. from a Latin American country with the intention of staying in the U.S.A. for at least three years beyond baseline. Respondent-driven sampling was applied. Results showed that since arriving in the U.S.A. approximately 6.3% of all participants had engaged in DWI at least once and 20% reported RWID. Although household income and being male were significant factors, the factor that influenced post-immigration DWI/RWID the most was pre-immigration DWI (odds ratio = 13.1) and pre-immigration RWID (odd ratio = 24.5). Interventions aimed to prevent recent immigrants from engaging in DWI and RWID should take cultural factors and pre-immigration behaviors into account.


2001 ◽  
Vol 29 (3) ◽  
pp. 47-52
Author(s):  
Geoff Lindsay
Keyword(s):  

2015 ◽  
Vol 62 (4) ◽  
pp. 211-217 ◽  
Author(s):  
Malik M. Parmar ◽  
K.S. Sachdeva ◽  
Kiran Rade ◽  
Mayank Ghedia ◽  
Avi Bansal ◽  
...  

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Abdou Amza ◽  
Boubacar Kadri ◽  
Beido Nassirou ◽  
Ahmed M. Arzika ◽  
Ariana Austin ◽  
...  

Abstract Background The World Health Organization (WHO) recommends annual mass azithromycin distribution until districts drop below 5% prevalence of trachomatous inflammation—follicular (TF). Districts with very low TF prevalence may have little or no transmission of the ocular strains of Chlamydia trachomatis that cause trachoma, and additional rounds of mass azithromycin distribution may not be useful. Here, we describe the protocol for a randomized controlled trial designed to evaluate whether mass azithromycin distribution can be stopped prior to the current WHO guidelines. Methods The Azithromycin Reduction to Reach Elimination of Trachoma (ARRET) study is a 1:1 community randomized non-inferiority trial designed to evaluate whether mass azithromycin distribution can be stopped in districts with baseline prevalence of TF under 20%. Communities in Maradi, Niger are randomized after baseline assessment either to continued annual mass azithromycin distribution or stopping annual azithromycin distribution over a 3-year period. We will compare the prevalence of ocular C. trachomatis (primary outcome), TF and other clinical signs of trachoma, and serologic markers of trachoma after 3 years. We hypothesize that stopping annual azithromycin distribution will be non-inferior to continued annual azithromycin distributions for all markers of trachoma prevalence and transmission. Discussion The results of this trial are anticipated to provide potentially guideline-changing evidence for when mass azithromycin distributions can be stopped in low TF prevalence areas. Trial registration number This study is registered at clinicaltrials.gov (NCT04185402). Registered December 4, 2019; prospectively registered pre-results.


2017 ◽  
Vol 1 (suppl_1) ◽  
pp. 1086-1086
Author(s):  
R. Yu ◽  
J. Woo ◽  
T. Lum ◽  
V. Lou ◽  
C. Ma ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document